Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 184
- 试验地点
- 4
研究概览
简要总结
The purpose of this study is to determine the effectiveness and safety of using the Medstone lithotripter to treat single non-calcified gallstones from 4 to 20 mm in diameter.
详细描述
This study is a randomized, single-masked controlled trial in which the combination therapy of lithotripsy and the bile acid drug Actigall is compared to monotherapy with only Actigall. The primary objectives are, 1) To determine whether the use of the Medstone STS Lithotripter system in combination with the orally administered drug Actigall is more effective (as measured by percentages of stone free patients 6 months after randomization) in reducing single non-calcified radiolucent gallstones (from 4 to 20mm in diameter) than use of Actigall alone, and 2) To demonstrate that use of the Medstone lithotripsy system is safe (as measured by incidence of adverse events) for the intended purpose, when operated according to its labeling.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 90 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •History of biliary pain
- •Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (inclusive) diameter
- •HIDA scan demonstrating patency of cystic bile duct
- •No cardiac pacemaker
- •No allergy to radioopaque dye, iodine, bile acids
- •No spontaneous or iatrogenic bleeding disorder
- •No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis
- •Not pregnant
排除标准
- 未提供
